Dr Reddys Laboratories Ltd Share Price
(DRREDDY)
₹1176
as on 04:01PM, 29 Apr 2025
Dr Reddy's Laboratories Performance
Day's Low
Day's High
₹1,169Day's Price Range₹1,204.452 Week's Low
52 Week's High
₹1,02052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | + 2.07 % |
| 3 Month Return | -1.55 % |
| 1 Year Return | -5.23 % |
| Market Stats | |
| Previous Close | ₹1,198.70 |
| Open | ₹1,204.40 |
| Volume | 16.63L |
| Upper Circuit | ₹1,318.50 |
| Lower Circuit | ₹1,078.90 |
| Market Cap | ₹98,131.95Cr |
Dr Reddy's Laboratories Fundamentals
P/E Ratio
18.23
PEG Ratio
11.18
Market Cap
₹98,131.95 Cr
P/B Ratio
4.22
EPS
66.882
Dividend Yield
0.65
Sector
Pharmaceuticals
ROE
19.42
Mutual Fund Holdings of Dr Reddy's Laboratories
Dr Reddy's Laboratories Analyst Rating
based on 38 analysts
36.84%
Buy
28.95%
Hold
34.21%
Sell
Based on 38 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1321.8
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share analysis
Dr Reddy's Laboratories price forecast by 38 analysts
Upside of12.40%
High
₹1723
Target
₹1321.80
Low
₹943
Dr Reddy's Laboratories target price ₹1321.8, a slight upside of 12.4% compared to current price of ₹1176. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:25.06%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Dr Reddys Laboratories Ltd
Dr. Reddys Expands Partnership to Launch Beyfortus - 28 Apr, 2025
Dr. Reddys Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in newborns, expected to launch in Q2 FY26.ICMR Proposes Ban on Dr Reddy's Nimesulide Drug - 23 Apr, 2025
The ICMR has suggested a selective ban on Nimesulide, affecting Dr Reddy's Laboratories' leading brand, Nise, amidst a growing market for the drug.Dr Reddys Issues Class 1 Recall in US Market - 22 Apr, 2025
Dr Reddys Laboratories is recalling 4,010 bags of Levetiracetam 0.75% Sodium Chloride Injection in the US due to a labelling error. The recall is classified as Class 1, indicating potential serious health risks.Dr Reddy's Stock Shows Modest Gains - 18 Apr, 2025
Dr Reddy's Laboratories Ltd shares rose by 0.42% to Rs 1163, with a market capitalization of Rs 97,735 crores. The stock is fairly valued with a P/E ratio of 18, trading at a 17% discount from its 52-week high of Rs 1,420.20.Dr. Reddy's Laboratories Faces Challenges Amidst Growth Plans - 16 Apr, 2025
Dr. Reddy's Laboratories maintains a strong position in the U.S. generics market, focusing on complex generics. However, the stock has declined 8% over the past year, with unchanged EPS estimates for fiscal 2026. The company holds a Zacks Rank #3 (Hold).Dr Reddy’s Shares Rise Amid Denials and Acquisitions - 15 Apr, 2025
Dr Reddy’s Laboratories shares experienced a rise following the company's denial of workforce cut rumors and positive brokerage ratings. The company is also in discussions to acquire Sanofi's Lantus. Overall, the stock showed strong performance amid increased trading volume and positive financial indicators.Dr Reddy's Denies Workforce Cost Reduction Claims - 14 Apr, 2025
Dr Reddy's Laboratories has categorically denied media reports about a 25% workforce cost reduction, labeling them as factually incorrect. The company emphasized it does not comment on market speculations.Dr Reddy's Laboratories Implements Major Downsizing - 13 Apr, 2025
Dr Reddy's Laboratories is reducing workforce costs by 25%, potentially laying off 300-400 employees, primarily those in higher salary brackets. This move aims to offset margin pressures from declining Revlimid sales while maintaining operational efficiency and double-digit growth.Dr Reddy's Faces Tax Demand of Rs 2,396 Crore - 11 Apr, 2025
Dr Reddy's Laboratories received a show-cause notice from tax authorities demanding Rs 2,396 crore, linked to a tax issue from its 2022 merger with Dr Reddy's Holding Ltd.Dr Reddy's Reports Profit Amid Stock Decline - 10 Apr, 2025
Dr Reddy's Laboratories reported a Q3 net profit of Rs 27.9 crore, recovering from a loss last year. However, the stock fell 3.11% following the results amid broader pharma sector declines due to tariff concerns.Dr Reddy's Faces Tariff Concerns Amid IT Partnership - 09 Apr, 2025
Dr Reddy's Laboratories faces a 4% stock decline following Trump's tariff announcement on pharmaceuticals. Meanwhile, the company partners with Kyndryl to improve IT operations using AI technology.Dr. Reddy's Faces Tax Notice Amid Earnings Report - 05 Apr, 2025
Dr. Reddy's Laboratories reported a 14.7% revenue increase in Q3 FY25. The company also received a ₹2,395 crore tax reassessment notice related to a merger, asserting compliance with tax laws and plans to respond appropriately.Dr Reddy's Laboratories Faces Mixed Performance - 04 Apr, 2025
Dr Reddy's Laboratories shares have declined 19.5% YTD and 17% over six months, but long-term returns remain positive. Domestic sales are expected to grow 21% YoY, driven by the Sanofi portfolio integration, while US sales growth is projected at only 3% YoY in Q4FY25.Dr Reddys Shares Surge on US Tariff Relief - 03 Apr, 2025
On April 3, 2025, Dr Reddys Laboratories shares rose significantly as US President Trump excluded pharmaceuticals from new tariffs, leading to a 5% increase. The overall sentiment in the pharma sector was positive, with stocks opening higher and gaining throughout the day.Dr Reddy's Faces Margin Pressure from Tariffs - 02 Apr, 2025
Dr Reddy's Laboratories is likely to experience margin pressure due to potential tariff increases affecting export costs, particularly given its high reliance on the US market.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, DRREDDY stock has moved up by 2.0%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.14% to 12.89% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Mar 2025 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 10.22% to 10.15% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 26.85% to 25.75% in Mar 2025 quarter
Dr Reddy's Laboratories Financials
Dr Reddy's Laboratories Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 25.75% | 0.00 | |
| Mutual Funds | 12.88% | 0.00 | |
| Retail Investors | 10.15% | 0.00 | |
| Others | 24.57% | 0.00 |
Dr Reddy's Laboratories Key Indicators
Dr Reddy's Laboratories Valuation
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.23x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (53.88x)
December 18, 2020
Dr Reddy's Laboratories Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.80%.
Read More about Dividends
Dr Reddy's Laboratories Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
Dr Reddy's Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹98,131.95 Cr | 9.88% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,62,148.21 Cr | 32.36% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,12,450.22 Cr | 36.67% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,281.13 Cr | -1.98% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,278.43 Cr | -4.47% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Dr Reddys Laboratories Ltd
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1176, Open: ₹1204.4, Previous Close: ₹1198.7, High: ₹1204.4, Low: ₹1169, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 16.63L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹98131.95Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1176. It is down -17.27% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1176. It is up 15.29% from its 52 Week Low price of ₹1020